Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy

Aurélie Mbeutcha, Laurent Chauveinc, Pierre-Yves Bondiau, Marie-Eve Chand, Matthieu Durand, Daniel Chevallier, Jean Amiel, Daniel Lam Cham Kee, Jean-Michel Hannoun-Lévi, Aurélie Mbeutcha, Laurent Chauveinc, Pierre-Yves Bondiau, Marie-Eve Chand, Matthieu Durand, Daniel Chevallier, Jean Amiel, Daniel Lam Cham Kee, Jean-Michel Hannoun-Lévi

Abstract

Background: Optimal management of locally recurrent prostate cancer after definitive radiation therapy is still challenging. With the development of highly accurate radiotherapy devices, prostate salvage re-irradiation might generate lower toxicity rates than classical salvage therapies. We retrospectively evaluated the toxicity and the feasibility of a prostate re-irradiation after definitive radiation therapy failure. Two modalities were investigated: high-dose-rate brachytherapy (HDRB) on whole prostate gland and focal stereotactic radiotherapy (SBRT) using CyberKnife® linac.

Methods: Between 2011 and 2015, 28 patients with imaged and/or biopsy-proven intra-prostatic recurrence of cancer after definitive radiation therapy underwent a salvage re-irradiation using HDRB (n = 10) or focal SBRT (n = 18). The schedule of re-irradiation was 35 Gy in 5 fractions. Biological response (defined as post-salvage radiation PSA variation) and biochemical no-evidence of disease (bNED) were evaluated in the whole cohort. For patients who had a positive biological response after salvage radiation, biochemical recurrence (BCR) and survival after salvage radiotherapy were evaluated. Post-salvage toxicities were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 and were compared to baseline status.

Results: Within a median follow-up of 22.5 months (IQR = 8-42), 9 (90%) patients experienced a positive biological response after salvage HDRB and 5 (50%) remained bNED at the end of the follow-up. Among patients who initially responded to salvage HDRB, the BCR rate was 44.4% after a median interval of 19.5 months (IQR = 11.5-26). Only one patient experienced a transient grade 3 urinary complication. In the SBRT group, the median follow-up was 14.5 months (IQR = 7-23) and 10 (55.6%) out of the 18 patients remained bNED. Among the 15 patients who initially responded to salvage SBRT, 5 (33.3%) experienced a BCR. One patient experienced a transient grade 4 urinary complication. At the end of the follow-up, all evaluated patients had a urinary status grade variation ≤ +1 grade. No grade 3-4 digestive toxicity was observed.

Conclusions: Salvage prostate re-irradiation for locally recurrent cancer is feasible and generate low toxicities rates when using with HDRB or focal SBRT. However, further investigations are necessary to confirm these findings and to determine predictive features for patients who might benefit from such an approach.

Keywords: CyberKnife; High-dose-rate brachytherapy; Local recurrence; Prostate cancer; Salvage therapy; Stereotactic body radiation therapy.

Figures

Fig. 1
Fig. 1
Patients’ flow chart
Fig. 2
Fig. 2
Biochemical recurrence-free survival after salvage high-dose-rate brachytherapy (n = 10) and stereotactic body radiation therapy (n = 18)

References

    1. Neppl-Huber C, et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era : additional diagnoses and avoided deaths. Ann Oncol. 2012:1325–1334. doi:10.1093/annonc/mdr414.
    1. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR. Treatment Failure After Primary and Salvage Therapy for Prostate Cancer: likehood, patterns of care and outcomes. Cancer. 2007;112.
    1. Tran H, Kwok J, Pickles T, Tyldesley S, Black PC. Underutilization of local salvage therapy after radiation therapy for prostate cancer. Urol Oncol. 2014;32:701–706. doi: 10.1016/j.urolonc.2013.12.014.
    1. Ahmadi H, Daneshmand S. Androgen deprivation therapy : evidence-based management of side effects. BJU Int. 2013:543–548. doi:10.1111/j.1464-410X.2012.11774.x.
    1. Ramey SJ, Marshall DT. Re-irradiation for salvage of prostate cancer failures after primary radiotherapy. World J Urol. 2013;31:1339–1345. doi: 10.1007/s00345-012-0953-7.
    1. Boukaram C, Hannoun-Levi J. Management of prostate cancer recurrence after definitive radiation therapy. Cancer Treat Rev. 2010;36:91–100. doi: 10.1016/j.ctrv.2009.06.006.
    1. Heidenreich A, et al. EAU Guidelines on Prostate Cancer. Part II : Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol. 2013;65:467–479. doi: 10.1016/j.eururo.2013.11.002.
    1. Nguyen PL, D’Amico AV, Lee AK, Suh WW. Patient Selection, Cancer Control, and Complications After Salvage Local Therapy for Postradiation Prostate-specific Antigen Failure/A Sytematic Review of the Literature. Cancer. 2007;110:1417–1428. doi: 10.1002/cncr.22941.
    1. Henríquez I, et al. Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity. Radiat Oncol. 2014;9:102. doi: 10.1186/1748-717X-9-102.
    1. Vargas C, et al. Salvage brachytherapy for recurrent prostate cancer. Brachytherapy. 2014;13:53–58. doi: 10.1016/j.brachy.2013.10.012.
    1. Fukuda S, et al. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife. J Radiat Res. 2014;55:1114–1121. doi: 10.1093/jrr/rru048.
    1. Sudahar H, Kurup PGG, Murali V, Mahadev P, Velmurugan J. Medical Dosimetry Analysis of high – dose rate brachytherapy dose distribution resemblance in CyberKnife hypofractionated treatment plans of localized prostate cancer. Med Dosim. 2013;38:385–389. doi: 10.1016/j.meddos.2013.04.006.
    1. Chen CP, et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013;86:324–329. doi: 10.1016/j.ijrobp.2013.01.027.
    1. Jo Y, et al. Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy – preliminary results. BJU Int. 2011;109:835–839. doi: 10.1111/j.1464-410X.2011.10519.x.
    1. Lee B, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the university of California-San Francisco experience. Int J Radiat Oncol Biol Phys. 2007;67:1106–1112. doi: 10.1016/j.ijrobp.2006.10.012.
    1. Tharp M, et al. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy. 2008;7:231–236. doi: 10.1016/j.brachy.2008.03.003.
    1. Yamada Y, et al. A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy. 2014;13:111–116. doi: 10.1016/j.brachy.2013.11.005.
    1. Vavassori A, et al. Image-guided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation : retrospective feasibility study on six cases. Tumori. 2010;96:71–75.
    1. Zerini D, et al. Salvage image-guided intensity modulated or stereotactic body reirradiation of local recurrence of prostate cancer. Br J Radiol. 2015;88:20150197. doi: 10.1259/bjr.20150197.
    1. Fuller DB, Wurzer J, Shirazi R, Bridge SS, Law J, Mardirossian G. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment. Pract Radiat Oncol. 2015;5(6):e615–23. doi: 10.1016/j.prro.2015.04.009.
    1. National Cancer Institute, Common Terminology Criteria for Adverse Events v4.03, NCI, NIH. DHHS. 2009. . Accessed 4 Mar 17.
    1. Benedict SH, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37:4078–4101. doi: 10.1118/1.3438081.
    1. Claren A, Gautier M, Feuillade J, Falk AT, Hannoun-Levi JM. Second salvage treatment for local recurrence of prostate cancer using high-dose-rate brachytherapy: A case report. J Contemp Brachytherapy. 2015;7:244–247. doi: 10.5114/jcb.2015.51852.
    1. Simnor T, et al. Justification for inter-fraction correction of catheter movement in fractionated high dose-rate brachytherapy treatment of prostate cancer. Radiother Oncol. 2009;93:253–258. doi: 10.1016/j.radonc.2009.09.015.
    1. Hoskin PJ, et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol. 2013;107:325–332. doi: 10.1016/j.radonc.2013.05.002.
    1. Wojcieszek P, Szlag M, Głowacki G, Cholewka A. Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy failure. Radiother Oncol. 2016;119:405–410. doi: 10.1016/j.radonc.2016.04.032.
    1. Ohri N, Dicker AP, Showalter TN. Late toxicity rates following definitive radiotherapy for prostate cancer. Can J Urol. 2012;19:6373–6380.
    1. Parekh A, Graham PL, Nguyen PL. Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: A systematic review. Semin Radiat Oncol. 2013;23:222–234. doi: 10.1016/j.semradonc.2013.01.006.
    1. Matei DV, et al. Salvage Radical Prostatectomy after External Beam Radiation Therapy : A Systematic Review of Current Approaches. Urol Int. 2015;94:373–382. doi: 10.1159/000371893.
    1. Peters M, et al. Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review. World J Urol. 2013;31:403–409. doi: 10.1007/s00345-012-0928-8.
    1. Janoray G, Reynaud-bougnoux A, Ruffier-loubière A, Bernadou G. Stereotactic body re-irradiation therapy for locally recurrent prostate cancer after external-beam radiation therapy : Initial report Ré-irradiation stéréotaxique robotisée de récidive locale de cancer de prostate après radiothérapie externe : résultats p. Cancer/Radiother. 2016;20:275–281. doi: 10.1016/j.canrad.2016.03.005.
    1. Duijzentkunst DAS, Peters M, Van Der Voort van Zyp JRN, Moerland MA, van Vulpen M. Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy : a comprehensive review. World J Urol. 2016
    1. Kaljouw E, Pieters BR, Kovács G, Hoskin PJ. A Delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study. Radiother Oncol. 2015

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera